Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Launches NextGen Portal for Reporting Drug Volume Data

  • Post author:PacConAdmin
  • Post published:December 3, 2021
  • Post category:Drug GMP Report

After a delay in 2020, the FDA has launched its new NextGen Portal for drug manufacturers to use for reporting volume data for drugs and biologics. Source: Drug GMP Report

Continue ReadingFDA Launches NextGen Portal for Reporting Drug Volume Data

Dercher Enterprises Hit With Fourth 483 in 13 Years

  • Post author:PacConAdmin
  • Post published:December 3, 2021
  • Post category:Drug GMP Report

Dercher Enterprises of Upper Darby, Pa., doing business as Gordon Laboratories, was hit with an eight-observation Form 483, and the company’s new quality director told FDAnews that he’s working to…

Continue ReadingDercher Enterprises Hit With Fourth 483 in 13 Years

Chinese API Manufacturer Draws FDA Warning Letter

  • Post author:PacConAdmin
  • Post published:December 3, 2021
  • Post category:Drug GMP Report

The FDA has closed out its three-year-old warning letter to Zhejiang Huahai Pharmaceutical’s site in Linhai, Taizhou because of corrective actions the manufacturer has undertaken. Source: Drug GMP Report

Continue ReadingChinese API Manufacturer Draws FDA Warning Letter

Government’s $600M Contract With Troubled Emergent Vaccine Plant is No More

  • Post author:PacConAdmin
  • Post published:December 3, 2021
  • Post category:Drug GMP Report

Following a year in which vaccine manufacturing plant Emergent BioSolutions spent many months in the headlines for botching 75 million Johnson & Johnson (J&J) COVID-19 vaccines, the federal government and…

Continue ReadingGovernment’s $600M Contract With Troubled Emergent Vaccine Plant is No More

United Therapeutics Draws CRL for Drug-Device Combination

  • Post author:PacConAdmin
  • Post published:November 1, 2021
  • Post category:Drug GMP Report

In a Complete Response Letter to United Therapeutics, the FDA declined to approve the company’s Tyvaso DPI (treprostinil) drug-device combination for improving exercise capacity in patients with pulmonary arterial hypertension…

Continue ReadingUnited Therapeutics Draws CRL for Drug-Device Combination

FDA Releases Guidance on ICH Q13 Continuous Manufacturing Concepts

  • Post author:PacConAdmin
  • Post published:November 1, 2021
  • Post category:Drug GMP Report

The FDA has released draft guidance on continuous manufacturing concepts for drug substances and drug products. Source: Drug GMP Report

Continue ReadingFDA Releases Guidance on ICH Q13 Continuous Manufacturing Concepts

House Passes Bill to Promote Continuous Drug Manufacturing

  • Post author:PacConAdmin
  • Post published:November 1, 2021
  • Post category:Drug GMP Report

The House of Representatives passed a bill in a bipartisan 368-56 vote on Oct. 19 that aims to promote innovation in continuous manufacturing, which is used to produce drugs more…

Continue ReadingHouse Passes Bill to Promote Continuous Drug Manufacturing

Teva Pharmaceutical Halts Drug Production at Irvine, Calif., Plant

  • Post author:PacConAdmin
  • Post published:November 1, 2021
  • Post category:Drug GMP Report

Teva Pharmaceutical stopped drug manufacturing at its Irvine, Calif., facility following a recent FDA inspection that revealed lapses, including possible mold contamination caused by water leaks. Source: Drug GMP Report

Continue ReadingTeva Pharmaceutical Halts Drug Production at Irvine, Calif., Plant

483 Roundup: FDA Raps Four Firms for Quality Deficiencies

  • Post author:PacConAdmin
  • Post published:November 1, 2021
  • Post category:Drug GMP Report

Cleaning and maintenance lapses feature among the deficiencies observed by FDA investigators during inspections of four drug facilities. Source: Drug GMP Report

Continue Reading483 Roundup: FDA Raps Four Firms for Quality Deficiencies

Warning Letter Roundup: Four Drug Facilities Draw Warnings for GMPs

  • Post author:PacConAdmin
  • Post published:November 1, 2021
  • Post category:Drug GMP Report

The FDA issued warning letters to four drug manufacturing plants for failure to maintain good manufacturing practices — and to one firm for producing misbranded and unapproved drug products. Source:…

Continue ReadingWarning Letter Roundup: Four Drug Facilities Draw Warnings for GMPs
  • 1
  • 2
  • 3
  • 4
  • …
  • 39
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.